Biofortuna Raises £1.3M in Funding

Biofortuna, a Wirral, UK-based diagnostics company, raised £1.3m in funding.

Backers included all current investors Enterprise Ventures, the Foresight Group (UK), Catapult Venture Managers, Merseyside Special Investment Fund, private investors and management.

The company intends to use the funds to expand its manufacturing capability to support both its custom service clients and the USA launch of its SSPGo HLA range of products.

Launched in 2008 and led by Dr Simon Douglas, CEO, Biofortuna has developed a method to stabilize molecular diagnostic products using its proprietary freeze-dried technology. Current tests are stored and transported frozen and must then be carefully thawed and mixed prior to the addition of the patient’s DNA.
The company also has its own range of stabilized products, SSPGo, and has partnered with Abbott Molecular as a global exclusive distributor for these kits.



Related News
27/05/2010: Biofortuna Raises £1.1M from EV Tech and Catapult Venture Managers
11/04/2012: Biofortuna Raises £2.1M in Funding

Join the discussion